Data were published in The Lancet today from a Phase IIb clinical
trial evaluating the safety and efficacy of MVA85A in preventing
tuberculosis (TB) in infants. MVA85A is a TB vaccine candidate designed
to boost immune responses already primed by the Bacille Calmette-Guérin
(BCG) vaccine, the currently licensed and widely used TB vaccine.
Data show that a single dose of MVA85A is not sufficient to confer
statistically significant protection against TB disease or infection in
infants who had been vaccinated at birth with BCG. There were 32 cases
of TB disease in the infants that received BCG + MVA85A compared with 39
cases of disease among those receiving BCG + placebo. Non-significant
vaccine efficacy was measured at 17.3% (95% CI -31.9% to
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in